CSPC Pharmaceutical Group's (HKG:1093) SYH2083 eye drops received approval from the National Medical Products Administration to begin clinical trials in China.
The class 1 innovative drug is being developed for dry eye disease, according to a Tuesday Hong Kong bourse filing.